ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 パーキンソン病診療の現在地—200年の変遷と新規治療
文献概要
ここ10年にわたっていくつかの遅延開始研究が実施され，早期のドパミン補充療法導入がパーキンソン病の予後を改善する可能性が示唆されてきた。またL-ドパ毒性がほぼ否定的となったこともあり，『パーキンソン病診療ガイドライン2018』では原則としてL-ドパで治療を開始することが推奨されている。さらに最近，パーキンソン病に対する疾患修飾療法の臨床研究が目覚ましい勢いで進んでいる。運動が疾患予後を改善する可能性も注目される。
参考文献
1)日本神経学会（監修）, 「パーキンソン病診療ガイドライン」作成委員会（編）: パーキンソン病診療ガイドライン2018. 医学書院, 東京, 2018
2)日本神経学会治療ガイドライン パーキンソン病治療ガイドライン2002. 医学書院, 東京, 2002
3)日本神経学会（監修）, 「パーキンソン病治療ガイドライン」作成委員会（編）: パーキンソン病治療ガイドライン2011. 医学書院, 東京, 2011
4)福井次矢, 山口直人（監修）: Minds診療ガイドライン作成の手引き2014. 医学書院, 東京, 2014
5)Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-455, 1973
6)Marsden CD: Parkinson's disease. Lancet 335: 948-952, 1990
7)Fearnley JM, Lees AJ: Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114: 2283-2301, 1991
8)Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, et al: Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 62: 378-382, 2005
9)Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176-183, 1993
10)Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59: 1937-1943, 2002
11)Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, et al: A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361: 1268-1278, 2009
12)Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, et al: Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol 12: 747-755, 2013
13)Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, et al: Randomized delayed-start trial of levodopa in Parkinson's disease. N Engl J Med 380: 315-324, 2019
14)Shoulson I, Oakes D, Fahn S, e Lang A, Langston JW, t al: Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51: 604-612, 2002
15)Pålhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, et al: Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66: 1200-1206, 2006
16)Parkinson Study Group: A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61: 561-566, 2004
17)Lew MF, Hauser RA, Hurtig HI, Ondo WG, Wojcieszek J, et al: Long-term efficacy of rasagiline in early Parkinson's disease. Int J Neurosci 120: 404-408, 2010
18)Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, et al: Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 24: 564-573, 2009
19)Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, et al: The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain 137: 2731-2742, 2014
20)Fox SH, Lang AE: ‘Don't delay, start today’: delaying levodopa does not delay motor complications. Brain 137: 2628-2630, 2014
21)Clarke CE, Patel S, Ives N, Rick C, Wheatley K, et al: Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? Mov Disord 26: 1187-1193, 2011
22)Goetz CG, Poewe W, Rascol O, Sampaio C: Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 20: 523-539, 2005
23)Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, et al: Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 21: 343-353, 2006
24)Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, et al: Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71: 474-480, 2008
25)PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, et al: Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384: 1196-1205, 2014
26)Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, et al: Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 28: 1064-1071, 2013
27)Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, et al: Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord 25: 858-866, 2010
28)Tolosa E, Wenning G, Poewe W: The diagnosis of Parkinson's disease. Lancet Neurol 5: 75-86, 2006
29)Fahn S: Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 56: 529-535, 1999
30)Mizuno Y, Yanagisawa N, Kuno S, Yamamoto M, Hasegawa K, et al: Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord 18: 1149-1156, 2003
31)Mizuno Y, Abe T, Hasegawa K, Kuno S, Kondo T, et al: Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. Mov Disord 22: 1860-1865, 2007
32)Mizuno Y, Hattori N, Kondo T, Nomoto M, Origasa H, et al: A randomized double-blind placebo-controlled phase III trial of selegiline monotherapy for early Parkinson disease. Clin Neuropharmacol 40: 201-207, 2017
33)Hattori N, Takeda A, Takeda S, Nishimura A, Kitagawa T, et al: Rasagiline monotherapy in early Parkinson's disease: a phase 3, randomized study in Japan. Parkinsonism Relat Disord pii: S1353-8020(18)30383-3, 2018［doi: 10.1016/j.parkreldis.2018.08.024］
34)Yang F, Trolle Lagerros Y, Bellocco R, Adami HO, Fang F, et al: Physical activity and risk of Parkinson's disease in the Swedish National March Cohort. Brain 138: 269-275, 2015
35)Tomlinson CL, Herd CP, Clarke CE, Meek C, Patel S, et al: Physiotherapy for Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev (6): CD002815, 2014［doi: 10.1002/14651858］
36)Tomlinson CL, Patel S, Meek C, Clarke CE, Stowe R, et al: Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev (7): CD002817, 2012［doi: 10.1002/14651858.CD002817］
37)Wu PL, Lee M, Huang TT: Effectiveness of physical activity on patients with depression and Parkinson's disease: a systematic review. PLOS ONE 12: e0181515, 2017［doi: 10.1371/journal.pone.0181515］
38)Coelho FG, Gobbi S, Andreatto CA, Corazza DI, Pedroso RV, et al: Physical exercise modulates peripheral levels of brain-derived neurotrophic factor (BDNF): a systematic review of experimental studies in the elderly. Arch Gerontol Geriatr 56: 10-15, 2013
39)Lu B, Nagappan G, Guan X, Nathan PJ, Wren P: BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci 14: 401-416, 2013
40)Mittal S, Bjørnevik K, Im DS, Flierl A, Dong X, et al: β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. Science 357: 891-898, 2017
41)Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, et al: Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 390: 1664-1675, 2017
42)Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, et al: Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol 75: 1206-1214, 2018
43)Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, et al: Development of an aggregate-selective, human-derived aα-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. Neurobiol Dis 124: 276-288, 2019［doi: 10.1016/j.nbd.2018.10.016］
掲載誌情報
